Homburger advises specialty vaccines company PaxVax in its sale to Emergent BioSolutions
On August 9, 2018, PaxVax Inc., a U.S. company focused on specialty vaccines, announced that it had entered into a definitive agreement to be acquired by Emergent BioSolutions Inc. (NYSE: EBS), a global life sciences company focused on providing specialty products against public health threats, for an all-cash consideration of USD 270 m. The transaction is subject to customary closing conditions, including regulatory approval. PaxVax is majority owned by an affiliate of Cerberus Capital Management, L.P., and operates the former Berna production facility near Berne, Switzerland.
The Homburger team is led by partner Dieter Gericke (Corporate / M&A) and includes associates Daniel Häusermann and Karin Mattle (both Corporate / M&A) as well as associate Allegra Schär (Competition / Regulatory). Partner Peter Riedweg as well as associates Manuel Dubach and Laetitia Fracheboud provided tax advice.